TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05033457

Intervention type: PROCEDURE
Intervention: unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy
Description: Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.

Intervention type: PROCEDURE
Intervention: unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy
Description: Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
Study: NCT01101555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
Study: NCT04686890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinea plane block administered preoperative open nephrectomy
Description: erector spinae plane block applied in this group before open nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg
Description: intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
Study: NCT01101555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.
Study: NCT04686890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg
Description: intarvenous analgesic administered in this group for analgesia end of the open nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg
Description: intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
Study: NCT01101555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.
Study: NCT02025036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine(Aibin)
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine(Aibin)
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin(Aiheng)
Description: Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study: NCT03790969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 26 gauge needle
Description: smaller gauge needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 23 gauge needle
Description: control group
Study: NCT01783938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02991612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Patients receive Rifaximin 400mg bid for 2 months
Study: NCT02271490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acrosome Reaction induction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: capacitation in incubation medium prior to ICSI
Study: NCT00789204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
Study: NCT01783938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT03753477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
Description: DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevikar and Crestor
Description: Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
Study: NCT04663217

Intervention type: OTHER
Intervention: Exercise
Description: After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Intervention type: OTHER
Intervention: Exercise
Description: After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Intervention type: OTHER
Intervention: Exercise
Description: After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion

Intervention type: OTHER
Intervention: Exercise
Description: After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Study: NCT03812250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP assisted trans-papillary drainage for malignant biliary obstruction
Description: ERCP assisted trans-papillary drainage for malignant biliary obstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guide biliary drainage for malignant biliary obstruction
Description: EUS-guide biliary drainage for malignant biliary obstruction
Study: NCT01978574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intellectual Enrichment daily activities
Description: A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intellectual Enrichment documentary videos
Description: Participants watch daily documentary videos.
Study: NCT01522027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
Study: NCT01713140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 strength training set performed until contraction failure
Description: Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
Study: NCT06376227

Intervention type: PROCEDURE
Intervention: with or without Left Colic Artery Preservation
Description: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
Study: NCT00789204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Training
Description: The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
Study: NCT01613105

Intervention type: DRUG
Intervention: Acarbose (Precose/Glucobay, BAYG5421)
Description: Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
Study: NCT03435900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.
Description: All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotics intravenously
Description: 4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
Study: NCT03832231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Ultrasound technology to assess tissue stiffness
Study: NCT03261869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Study: NCT03478787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: Subcutaneous (SC) injection
Study: NCT01121575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
Study: NCT00804479

Intervention type: OTHER
Intervention: No intervention.
Study: NCT03315559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 IV infusion
Description: The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 IV infusion
Description: The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 via DPI
Description: GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
Study: NCT04500015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Study: NCT03315559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 via DPI
Description: GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 oral solution
Description: The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 oral solution
Description: The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
Study: NCT01610388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg IV GSK1322322/placebo
Description: 500mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg IV GSK1322322/placebo
Description: 500mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg oral GSK1322322/placebo
Description: 1000mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg IV GSK1322322/placebo
Description: 1000mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500mg oral GSK1322322/placebo dose
Description: 1500mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500mg IV GSK1322322/placebo
Description: 1500mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000mg IV GSK1322322J/placebo
Description: 2000mg IV
Study: NCT00393458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study: NCT01610388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000mg IV GSK1322322J/placebo
Description: 3000mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg IV GSK1322322J/placebo
Description: 1000mg IV
Study: NCT03377127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy Managed Diabetes Clinic (PMDC)
Description: The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
Study: NCT02413346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarecycline
Description: Administered based on participant's body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarecycline
Description: Administered based on participant's body weight.
Study: NCT02595554

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoirradiation
Description: External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
Study: NCT00393458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol
Description: Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol
Description: Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to formoterol
Description: Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
Study: NCT02119130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QGIT
Description: Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
Study: NCT02367092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
Study: NCT01259739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: dissolved in water twice-daily intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: dissolved in water twice-daily intervention
Study: NCT02024256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pads soaked in Magnesium sulfate solution

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cold pads soaked in water
Study: NCT02662439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Composition Monitor (BCM)
Description: In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Body Composition Monitor (BCM)
Description: In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
Study: NCT01933984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilators inhalation
Description: Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
Study: NCT02595554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Surgery
Description: Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
Study: NCT01933984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators inhalation
Description: Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met